SCHEMBL6440667

SCHEMBL6440667

N#Cc1cnc(N)nc1-c1cccs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.59
ADORA1 P30542 6/20 0.59
ADORA2B P29275 1/20 0.55
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
CDK1 P06493 1/20 0.51
KDR P35968 1/20 0.51
ALDH1A1 P00352 6/20 0.49
KDM4E B2RXH2 6/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
HPGD P15428 3/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2980649 0.78 CYP1A2 (0.49) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL2981824 0.76 CDK1 (0.47) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL24786993 0.76 FOS (0.49) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL6033525 0.75 CDK1 (0.61) ADORA2AADORA1CYP1A2CYP3A4CDK1
SCHEMBL6034022 0.74 ADORA1 (1.00) ADORA2AADORA1CDK1KDRALDH1A1
SCHEMBL28358205 0.74 CDK1 (0.44) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL11066262 0.72 MAPT (0.48) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL5451849 0.72 ADORA1 (0.64) ADORA2AADORA1ADORA2BCYP3A4CYP2C9
SCHEMBL3291066 0.71 CYP11B1 (0.43) ADORA2AADORA1ADORA2BCYP1A2CYP3A4
SCHEMBL1031032 0.71 CSNK2A1 (0.41) ADORA2AADORA1ADORA2BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.